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Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and
vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.
We assessed urinary F
2
-isoprostanes (F
2
-IsoPs), prostaglandin E
2
(PGE-M), prostacyclin (PGI-M), and thromboxane B
2
(TxB
2
)
in HIV-infected women switching to RAL-containing antiretroviral therapy (ART). Thirty-seven women (RAL = 17; PI/NNRTI =
20) with a median age of 43 years and BMI 32 kg/m2 completed week 24. TxB
2
increased in the RAL versus PI/NNRTI arm (+0.09
versus −0.02; 𝑃 = 0.06). Baseline PGI-M was lower in the RAL arm (𝑃 = 0.005); no other between-arm cross-sectional differences
were observed. In the PI/NNRTI arm, 24-week visceral adipose tissue change correlated with PGI-M (rho = 0.45; 𝑃 = 0.04) and
TxB
2
(rho = 0.44; 𝑃 = 0.005) changes, with a trend seen for PGE-M (rho = 0.41; 𝑃 = 0.07). In an adjusted model, age ≥ 50 years
(𝑁 = 8) was associated with increased PGE-M (𝑃 = 0.04). In this randomized trial, a switch to RAL did not significantly affect
urinary eicosanoids over 24 weeks. In women continuing PI/NNRTI, increased visceral adipose tissue correlated with increased
PGI-M and PGE-M. Older age (≥50) was associated with increased PGE-M. Relationships between aging, adiposity, ART, and
eicosanoids during HIV-infection require further study.
1. Introduction
Fat redistribution in HIV-infected patients is associated with
antiretroviral therapy (ART), including protease inhibitors
(PI) and nonnucleoside reverse transcriptase inhibitors
(NNRTI) [1, 2]. Central fat accumulation or lipohypertrophy
may be more common in women [3, 4] and has been
associatedwithmultiplemetabolic abnormalities and inflam-
mation in HIV-infected persons on ART [5–9]. Chronic HIV
infection is also associated with persistent inflammation [10],
and treating HIV infection improved endothelial function
in treatment-naı¨ve subjects with low cardiovascular disease
(CVD) risk [11]. Given the complex interactions between
chronic HIV infection and ART and the likelihood that
traditional Framingham prediction may underestimate car-
diovascular risk in HIV-infected persons on ART [12, 13],
novel biomarkers are needed to assess metabolic risk in HIV
infection and response to interventions.
Eicosanoids are endogenous products of arachidonic
acid metabolism involved in oxidant stress, inflammation,
and endothelial function, all of which are important in
atherosclerosis and cardiovascular disease pathogenesis [14].
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Biologic properties and metabolism of eicosanoids are com-
plex and are reviewed elsewhere [15–17]. Briefly, during
cellular stress, membrane phospholipids containing arachi-
donic acid are subjected to nonenzymatic peroxidation by
free radical species to generate a variety of biologically
active oxidation products, including F
2
-isoprostanes (F
2
-
IsoPs) which can cause vasoconstriction, platelet aggregation,
and oxidative tissue damage. Arachidonic acid can also be
released from membrane phospholipids and metabolized
by oxidizing enzymes during cellular stress. Metabolism by
cyclooxygenase (COX) enzymes yields a family of products
termed prostaglandins (PGs), including PGE
2
, which causes
vasodilation or vasoconstriction and/or vascular smooth
muscle proliferation; thromboxane A
2
(TxA
2
), which causes
vasoconstriction, platelet activation, and chemotaxis; and
prostacyclin (PGI
2
) which causes vasodilation and inhibits
platelet aggregation and vascular smooth muscle prolifera-
tion. With the exception of F
2
-IsoPs [15], parent eicosanoids
are unstable in and cannot be reliably assayed from plasma.
Prostaglandin metabolites, as well as F
2
-IsoPs, are stable
in urine and accurate indices of endogenous production
[18–21]. The primary PGE
2
urinary metabolite is 11-𝛼-
hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid
(PGE-M), while the major metabolites used to assess TxA
2
and PGI
2
production are 11-dehydro-thromboxane B
2
(TxB
2
)
and 2,3-dinor-6-keto-PGF
1𝛼
(PGI-M), respectively. Urinary
assays for PGE-M and F
2
-IsoP have low intra-individual
variation over one year [22].
In HIV-negative populations, urinary F
2
-IsoP corre-
lates with traditional CVD risk factors [23] and surrogate
measures of CVD including brachial artery flow-mediated
dilation and carotid intimamedia thickness [24, 25]. In obese
children and adolescents, plasma F
2
-IsoP was positively
correlated with visceral adipose tissue (VAT), a marker of
CVD risk [26]. Cigarette smoking is also associated with
higher eicosanoids [27–30]. In HIV-infected persons, cross-
sectional studies to date have identified associations between
higher F
2
-IsoP and lipoatrophy, lactic acidosis, virologic
suppression onART, heavy smoking, higher bodymass index
(BMI) and waist circumference, elevated liver transaminases
and hepatitis C virus (HCV) RNA, and female sex [31–35].
Early analyses suggested higher F
2
-IsoP in persons receiving
efavirenz or zidovudine [32], and lower levels in those on
nevirapine compared with other ART [34] but consistent
associations with specific ART drugs or classes have not been
seen. It is not yet clear why F
2
-IsoP levels are consistently
higher inwomen (HIV-infected and uninfected) than inmen.
A recent study of women in Haiti found higher levels of
cervical COX-2 and urinary PGE-M in HIV-infected women
than in uninfected women and a positive correlation between
systemic PGE-M and both plasma HIV RNA and cervical
COX-2 levels [36].
Raltegravir (RAL) is an HIV-1 integrase inhibitor that
has not been associated with metabolic perturbations or fat
redistribution during short- or long-term therapy [37–39].
A randomized, open label study was designed to assess the
effects of switching from PI- or NNRTI-based ART to a
RAL-based regimen in women with lipohypertrophy and
suppressedHIV-1 RNA on stable therapy [40]. Adipose tissue
volumes by computerized tomography (CT), anthropomet-
rics, and fasting metabolic parameters were performed. The
objectives of these secondary analyses were to determine (a)
the 24-week change in F
2
-IsoP and other urinary eicosanoid
metabolites and (b) correlations between 24-week changes in
F
2
-IsoP, other urinary eicosanoidmetabolites, and changes in
VAT, the primary outcome of the parent study. We hypothe-
sized that urinary F
2
-IsoP and other eicosanoid metabolites
would decrease after 24 weeks in women switching to RAL
compared to those continuing a PI/NNRTI and that these
decreases would correlate with decreased VAT.
2. Materials and Methods
Complete methods for the parent study have been pub-
lished previously [40]. Briefly, women with HIV-1 RNA
<50 copies/mL, stable ART including two NRTIs (tenofovir
or abacavir and emtricitabine or lamivudine) plus a PI or
NNRTI, and central adiposity (waist circumference >94 cm
or waist: hip > 0.88) were enrolled at five centers in North
America from September 2008 to July 2010 and randomized
1 : 1 to switch their PI/NNRTI to open label RAL 400mg
twice daily (RAL arm) or continue to present ART for 24
weeks (PI/NNRTI arm). Relevant exclusion criteria included
current use of metformin, thiazolidinediones, or andro-
gen therapy, use of growth hormone or growth hormone-
releasing factor in the six months prior to screening, change
or initiation of lipid-lowering therapy in the three months
prior to screening, and intent to significantly modify diet
or exercise habits during the study. The primary endpoint
of the parent trial was between-group change in percent of
VAT volume 24 weeks following a switch to RAL versus
continued PI or NNRTI. All study procedures were approved
by the institutional review boards of the participating insti-
tutions, and all subjects provided informed consent prior to
initiation of study procedures. Procedures were performed
in accordance with the ethical standards of the responsible
committee on human experimentation and with the Helsinki
Declaration of the World Medical Association.
2.1. Assessments
2.1.1. Anthropometric Measurements. Visceral and subcuta-
neous adipose tissue (VAT and SAT, resp.) volume was
measured via single slice L4-L5 CT scan at weeks 0 and
24. Scans were performed locally but standardized and read
centrally by a blinded reader at the Tufts University Body
Composition Center. Waist, hip, and neck circumferences
were performed according to AIDS Clinical Trials Group
standards [41] at weeks 0, 12, and 24.
2.1.2. Laboratory Assessments. Fasting (>8 hours) glucose,
lipoprotein profile, high-sensitivity C reactive protein
(hsCRP), and CD4+ T cell counts were assessed at weeks 0,
12, and 24. HIV-1 RNA (50 copies/mL assay sensitivity) was
measured at screening and weeks 4, 8, 12, and 24. Labs were
performed at the individual sites in real-time and according
to local standards.
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2.1.3. Urinary Eicosanoids. Clean-catch urine samples were
collected, and three-milliliter (mL) aliquots of urine were
stored at −80∘C until analysis. Samples were shipped
overnight on dry ice to the Vanderbilt University Eicosanoid
Core Laboratory where analyses were performed. Uri-
nary F
2
-IsoP, TxB
2
, and PGI-M were measured using gas
chromatography-negative ion chemical ionizationmass spec-
trometry employing stable isotope dilution methodology, as
described elsewhere [15, 18, 20, 42]. PGE-M was measured
by liquid chromatography-mass spectroscopy (LC-MS), as
previously described [19]. Results for all urinary metabolites
are presented as ng/mg urinary creatinine (cr). At one
study site, a freezer malfunction led to transient thawing of
urine samples from nine subjects. Urinary eicosanoid results
from these samples were not statistically different from the
other sites, and analyses with and without data from these
samples were performed (data not shown). As there were no
substantive changes in the results, we report results including
data from all sites.
2.2. Statistical Analysis. Baseline characteristics of the two
randomization groups were compared using the Mann-
Whitney 𝑈 test for continuous variables and Fisher’s exact
test for categorical variables. Analyses also included Spear-
man correlations between continuous baseline and 24-week
change variables. Median values and interquartile ranges
(IQR) are reported for continuous variables, and percentages
are reported for categorical data. Comparison of median
between-group 24-week change scores for eicosanoids was
performed using theWilcoxon signed-rank test.The primary
analysis was as-treated, excluding subjects who did not
remain on the study regimen and/or did not have an observed
primary endpoint. Generalized linearmodels assessed associ-
ations between eicosanoid changes and study arm, adjusting
for baseline PI use, BMI, smoking status, study site, and age
(≥50 versus <50 years). All statistical tests were two-sided
with a nominal𝑃 level of 0.05. Given the exploratory nature of
these analyses, we did not adjust results for multiple testing.
Data analysis and management was performed using SAS 9.2
(SAS Institute, Inc., Cary, NC, USA).
3. Results
3.1. Baseline Demographics. Sixty-one women were screened
and 39 enrolled in the trial. Eighteen subjects were random-
ized to the RAL arm and 21 to continue PI/NNRTI. One
subject from each arm withdrew for reasons unrelated to the
study intervention [40], leaving 37 subjects who completed
the week 24 primary endpoint. Complete demographic and
baseline clinical characteristics of the 37 participants included
in the as-treated analysis are provided in Table 1. At baseline,
the study groups were well balanced, with the exception of
the PI/NNRTI arm having a higher rate of current smoking
(60% versus 24%; 𝑃 = 0.045). The median age was 43 years,
BMI 32 kg/m2, and 75% of subjects self-identified as Black or
Hispanic. Sixty-two percent of subjects were on a PI at entry
(versus 38% NNRTI), and the most commonly prescribed
NRTI was tenofovir (78%).
3.2. Baseline Urinary Eicosanoids. Baseline median (IQR)
urinary F
2
-IsoP, PGE-M, PGI-M, and TxB
2
(ng/mg cr) were
2.14 (1.49–3.16), 8.07 (4.47–10.56), 0.10 (0.06–0.15), and 0.46
(0.25–0.73), respectively (Table 1). When comparing study
arms, baselines PGI-M, PGE-M, and TxB
2
were all lower, and
F
2
-IsoP was higher in the RAL arm (Table 1), but only PGI-
M was statistically different (𝑃 = 0.005). Baseline PGE-M
tended to be higher in current smokers (𝑃 = 0.1; data not
shown). Eicosanoid levels also tended to differ by baseline
NRTI, with women receiving abacavir having consistently
lower levels (Figure 1), including statistically significantly
lower F
2
-IsoP (𝑃 = 0.05; Figure 1(a)) and TxB
2
(𝑃 = 0.04;
Figure 1(d)) levels.
3.3. Baseline Correlations between Urinary Eicosanoids and
Demographic and Metabolic Factors. Statistically significant
correlations were observed at baseline with PGE-M and
TxB
2
. PGE-M was positively correlated with age (rho =
0.34; 𝑃 = 0.04) and negatively correlated with body weight
(rho = −0.35; 𝑃 = 0.03). TxB
2
was positively correlated
with VAT:SAT and VAT:total adipose tissue and negatively
correlated with SAT, body weight, BMI, and hip and neck
circumferences (rho = −0.37 to −0.46; 𝑃 = 0.004 to 0.02).
None of the urinary eicosanoids were correlated with fasting
lipids, glucose, insulin resistance, or hsCRP in this study
population at baseline (data not shown).
3.4. Changes in Urinary Eicosanoids by Study Arm. Median
24-week urinary eicosanoid levels and changes from baseline
are shown in Figure 2 and Table 2. Over 24 weeks, only
PGI-M in RAL-treated subjects demonstrated a statistically
significantwithin-group change (𝑃 = 0.04; Figure 2(c)). TxB
2
increased in the RAL arm and decreased in the PI/NNRTI
arm (+0.09 [−0.04, +0.13] versus −0.02 [−0.20, +0.03];
Figure 2(d)), but this difference was of borderline statistical
significance (between-group 𝑃 = 0.06). There were no other
statistically significant differences between or within study
arms over 24 weeks. Age ≥ 50 years at baseline was associated
with an increase in PGE-M (median change +3.9 versus −1.3
in subjects <50 years of age; 𝑃 = 0.05; Figure 3). In the
PI/NNRTI arm, 24-week VAT change positively correlated
with changes in PGI-M (rho = 0.45; 𝑃 = 0.04) and TxB
2
(rho = 0.44; 𝑃 = 0.05), with a similar trend seen for PGE-
M (rho = 0.41; 𝑃 = 0.07). Among persons in the RAL arm,
the change in PGE-M correlated with an increase in HDL
cholesterol (rho = 0.56; 𝑃 = 0.02); this correlation was not
observed in the PI/NNRTI arm (rho = 0.17; 𝑃 = 0.48). No
other statistically significant correlations between lipids and
urinary eicosanoids were seen. Changes in eicosanoid levels
over 24weekswere not statistically different by baselineNRTI
(abacavir versus tenofovir; data not shown).
3.5. Adjusted Analyses of Changes in Urinary Eicosanoids.
Changes in urinary eicosanoids from baseline to 24 weeks
were assessed in multivariate models adjusting for study arm
(RAL versus PI/NNRTI), baseline BMI, age, PI use, smoking
status, and study site. Age ≥ 50 years (𝑁 = 8) was associated
with 24-week PGE-M increase (𝛽 = 8.3 [95% CI 0.3, 16.3];
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Table 1: Baseline characteristics of subjects completing 24 weeks of follow-up and included in eicosanoid analyses, total and by study arm.
Total (𝑁 = 37) RAL (𝑁 = 17) PI/NNRTI (𝑁 = 20)
Ethnicity
African-American 22 (59) 9 (53) 13 (65)
Hispanic 6 (16) 4 (24) 2 (10)
White 8 (22) 3 (18) 5 (25)
Asian 1 (3) 1 (6) 0 (0)
Age in years-median (range) 43 (26–57) 41 (26–51) 46 (31–57)
Weight (kg) 81.8 (73.9–105.0) 88.7 (81.0–105.0) 77.7 (71.7–97.0)
BMI (kg/m2) 32.0 (28.0–36.5) 34.7 (28.8–37.6) 30.4 (27.7–35.4)
VAT (cm2) 138 (100–154) 145 (105–154) 138 (93–154)
SAT (cm2) 432 (343–605) 450 (381–687) 420 (342–587)
VAT : SAT 0.25 (0.21–0.38) 0.25 (0.22–0.36) 0.25 (0.20–0.42)
Total cholesterol (mg/dL) 188.0 (162.0–214.0) 179.0 (162.0–206.0) 199.0 (164.5–221.5)
Triglycerides (mg/dL)c 118.0 (92.0–152.0) 116.0 (85.0–144.0) 129.0 (101.0–176.0)
LDL (mg/dL) 115.8 (93.0–128.0) 113.0 (103.0–123.0) 116 (89.0–138.1)
HDL (mg/dL) 49.0 (40.0–57.0) 47.6 (40.2–57.0) 49.1 (39.0–55.0)
Glucose (mg/dL) 87.0 (78.0–94.0) 84.0 (78.0–93.0) 88.5 (80.0–97.5)
Tobacco Use (Current) 16 (43) 4 (24)a 12 (60)a
Daily anti-inflammatory useb 14 (38) 7 (41) 7 (35)
CD4 count (cells/uL) 558 (422–747) 563 (447–747) 553 (354–770)
Baseline ART regimen
PI 23 (62) 11 (65) 12 (60)
NNRTI 14 (38) 6 (35) 8 (40)
NRTI
Abacavir 8 (22) 3 (18) 5 (25)
Tenofovir 29 (78) 14 (82) 15 (75)
Urinary eicosanoids (ng/mg cr) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD)
F2-IsoP 2.14 (1.49–3.16) 2.70 (2.09) 2.41 (1.96–3.04) 2.59 (1.14) 1.89 (1.35–3.77) 2.79 (2.67)
PGE-M (𝑁 = 36) 8.07 (4.47–10.56) 9.35 (6.77) 5.95 (4.25–9.52) 7.35 (6.07) 9.37 (5.36–13.48) 10.80 (7.10)
PGI-M (𝑁 = 36) 0.10 (0.06–0.15) 0.12 (0.08) 0.07 (0.05–0.10)c 0.08 (0.04) 0.13 (0.08–0.21)c 0.15 (0.09)
TxB2 0.46 (0.25–0.73) 0.53 (0.36) 0.34 (0.14–0.70) 0.45 (0.37) 0.55 (0.29–0.77) 0.60 (0.34)
Values shown are𝑁 (percentage), median (interquartile range [IQR]), or mean (standard deviation [SD]) except where noted.
aFisher’s exact 𝑃 = 0.045 for immediate versus delayed arm. bSeven women in each arm reported daily anti-inflammatory medication use: six in each arm
reported non-steroidal anti-inflammatory drug use; one in the RAL arm reported taking celecoxib, and one in the PI/NNRTI arm reported taking aspirin
81mg. cMann-Whitney 𝑈 𝑃 = 0.005 for RAL versus PI/NNRTI arm.
Abbreviations: ART = antiretroviral therapy; BMI = body mass index; F2-IsoP = F2-isoprostanes; HDL = high density lipoprotein cholesterol; LDL = low
density lipoprotein cholesterol; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor; PGE-M = prostaglandin E2
metabolite; PGI-M = prostacyclin metabolite; RAL = raltegravir; SAT = subcutaneous adipose tissue; TxB2= thromboxane B2; VAT = visceral adipose tissue.
𝑃 = 0.04), independent of the covariates above (Table 3). No
baseline factors were significantly associated with changes in
other urinary eicosanoids (Table 3).
4. Discussion
In these HIV-infected women with central adiposity and
suppressed HIV RNA on ART, switching PI- or NNRTI-
based ART to RAL did not have significant effects on urinary
eicosanoids over 24 weeks. Overall, F
2
-IsoP, PGE-M, and
TxB
2
levels were higher and PGI-M levels were lower than
published levels reported in healthy adults [15, 18–20, 43, 44].
Although formal comparisons were not performed, urinary
F
2
-IsoP (lower), PGE-M (higher), and TxB
2
(higher) levels
also differed from those observed in previously studied HIV-
infected women who were younger and had lower BMI [33].
Of note, several of the markers differed—though not with
statistical significance—at baseline between the two study
arms. Given known effects of smoking on these biomarkers
[27–29], this difference may have been driven in part by
the significantly greater number of smokers randomized to
the PI/NNRTI arm, and this may therefore have limited
our capacity to identify differences in changes over time
or due to RAL switch. Although baseline PGE-M tended
to be higher in current smokers (𝑁 = 16; median [IQR]
9.9 [4.9–14.4]) than nonsmokers (𝑁 = 21; median [IQR]
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Figure 1:Median baseline urinary eicosanoid levels by nucleoside reverse transcriptase inhibitor use. Panel (a) shows F
2
-IsoP; Panel (b) shows
PGE-M; Panel (c) shows PGI-M; Panel (d) shows TxB
2
. ∗
𝑃
value = 0.05; ∗∗
𝑃
value = 0.04. Black (x) lines indicate within-groupmedian; grey
dashed lines (-) indicate within-group 25th and 75th percentiles. F
2
-IsoPs: F
2
-isoprostanes; PGE-M: prostaglandin E
2
metabolite; PGI-M:
prostacyclin metabolite; TxB
2
: thromboxane B
2
. Units are ng/mg creatinine.
7.9 [4.0-10.0]; 𝑃 = 0.11), in a multivariate model, neither
current smoking nor study arm was significantly associated
with 24-week change in PGE-M and did not attenuate the
relationship between age and change in PGE-M.Additionally,
F
2
-IsoP, which is increased in HIV-infected and uninfected
smokers, tended to be higher in smokers at baseline (𝑃 =
0.06) but was not significantly higher in the PI/NNRTI arm.
Age and BMI were lower and higher in the RAL than the
PI/NNRTI arm, respectively (Table 1), and though they were
not statistically different, we did include these as covariates in
adjusted models.
In primary analyses, women in the switch arm had
significant improvements in total and LDL cholesterol but
did not have a statistically significant improvement in VAT
compared to women continuing an NNRTI or PI [40]. They
also had a significant decrease in soluble CD14, a marker
of monocyte activation [45]. A recent analysis of extensively
treatment experienced, predominantly male, subjects switch-
ing enfuvirtide to RAL in France reported significant 24-
week decreases in interleukin-6, D-dimer, and hsCRP [46]
that were not observed in these less treatment-experienced
women with central adiposity [45]. In subjects remaining on
PI/NNRTI, increasing VAT was marginally correlated with
increasing PGI-M and PGE-M over 24 weeks of follow-up,
suggesting a relationship between these markers and central
adiposity that was altered by a switch to RAL. Older age
(≥50 years) at enrollment was associated with an increase in
PGE-M independent of study arm, smoking status, PI use
at baseline, or other factors. Urinary eicosanoids other than
TxB
2
were not significantly associated with BMI at baseline.
This was unexpected given associations with F
2
-IsoP and
TxB
2
in prior cross-sectional studies of HIV-infected persons
[33, 34], and this may be due to the inclusion of both males
and females in prior analyses and/or the high prevalence of
obesity and relative lack of normal BMI ranges in this study
population.
This is the first study to prospectively assess the effects of
an ART switch on urinary eicosanoid metabolites. The small
sample size of our study and the imbalance of smokers in the
PI/NNRTI arm likely limited our ability to detect differences
between study arms. Nonetheless, intriguing trends and
preliminary associations were noted. Although not routinely
6 Mediators of Inflammation
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measured in clinical practice, eicosanoids are knownmarkers
of cardiovascular and metabolic disease risk in HIV-negative
populations. In particular, F
2
-IsoP has been associated with
CVDdisease risk factors, hsCRP, carotid intimamedial thick-
ness, coronary artery calcium, and angiographic coronary
artery obstruction [23, 24, 47]. Urinary TxB
2
was associated
with a composite clinical cardiovascular outcome [48]. PGE
2
is a complex mediator of inflammation and vasodilation with
variable effects on vascular tone depending on the tissue and
prostanoid receptor [49]. Increased PGE-M has also been
associated with malignancies in HIV-negative populations
[50–53], and urinary PGE-M correlated with plasma HIV
RNA and cervical COX-2 levels in a recent study of Haitian
women [36].
It was notable that baseline F
2
-IsoP and TxB
2
were
lower in subjects on abacavir. Abacavir exposure has been
associatedwith increased cardiovascular risk inHIV-infected
persons [54], but the association has not been consistent [55].
Although potential mechanism(s) are not clearly defined,
recent studies have reported abnormal platelet reactivity
with abacavir [56, 57]. To our knowledge, TxB
2
has not
been assessed in these or other studies. Lower F
2
-IsoP in
these abacavir-treated subjects and in a prior cross-sectional
analysis ofmen andwomen [33] suggests that if there is excess
cardiovascular risk due to abacavir, it is independent of lipid
peroxidation-related pathways; prospective studies would be
needed to determine this. Due to providers’ knowledge of
potential cardiovascular risk with abacavir and risk of renal
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Table 2: Urinary eicosanoid levels- absolute and 24-week changes, by study arm.
RAL Within-group 𝑃 PI/NNRTI Within-group 𝑃 Between-group 𝑃
F2-IsoP
Week 0 2.41 (1.96, 3.04) 1.89 (1.35, 3.77) 0.28
Week 24 2.39 (1.55, 2.65) 2.20 (1.17, 3.10) 0.96
Week 24 change −0.12 (−0.3, +0.08) 0.13 −0.13 (−0.62, +0.60) 0.70 0.82
PGE-M
Week 0 5.95 (4.25, 9.52) 9.37 (5.36, 13.48) 0.08
Week 24 6.96 (2.14, 8.51) 8.84 (5.77, 13.26) 0.08
Week 24 change +1.07 (−3.26, +3.08) 0.82 −1.25 (−3.29, +3.23) 0.81 0.77
PGI-M
Week 0 0.07 (0.05, 0.10) 0.13 (0.08, 0.21) 0.005
Week 24 0.08 (0.06, 0.13) 0.13 (0.10, 0.18) 0.04
Week 24 change +0.02 (−0.002, +0.05) 0.04 −0.004 (−0.04, +0.03) 0.62 0.08
TxB2
Week 0 0.34 (0.14, 0.70) 0.55 (0.29, 0.77) 0.09
Week 24 0.44 (0.27, 0.64) 0.44 (0.35, 0.61) 0.56
Week 24 change +0.10 (−0.04, +0.13) 0.22 −0.02 (−0.20, +0.03) 0.25 0.07
Values shown are median (interquartile range).
F2-IsoP = F2-isoprostanes; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PGE-M = prostaglandin E2 metabolite; PGI-M =
prostacyclin metabolite; RAL = raltegravir; TxB2 = thromboxane B2.
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Figure 3: Scatterplot of 24-week change in urinary PGE-M by
age < or ≥50 years. Between-group 𝑃 = 0.05. Black (x) lines
indicate within-groupmedian; grey dashed (-) lines indicate within-
group 25th and 75th percentiles. F
2
-IsoPs: F
2
-isoprostanes; PGE-M:
prostaglandin E
2
metabolite; PGI-M: prostacyclin metabolite; TxB
2
:
thromboxane B
2
. Units are ng/mg creatinine.
toxicity with tenofovir DF, it is also possible that abacavir
use is simply a marker of some other unmeasured factors
associated with risk for these conditions and lower urinary
eicosanoid levels.
In addition to the qualifications above, this analysis
has other limitations that should be noted. Use of aspirin
or nonsteroidal anti-inflammatory drugs (NSAID) was not
an exclusion criterion for the parent study, and detailed
information on dosing was not collected. Given the even
distribution of NSAID use across study arms (Table 1), we
did not adjust for this variable in multivariate models and do
not believe it would explain differential associations within or
between groups. Neither menopausal status nor sex hormone
levels were ascertained as part of this study. Based on data
from HIV-infected women [58], the age distribution of our
population suggests the majority of subjects were pre- or
perimenopausal. The association between age and PGE-M
may have been due to postmenopausal changes in the older
women (≥50 years). The number of older women included
in this study was small. Platelet reactivity assays were not
performed, so relationships between eicosanoids and platelet
function cannot be determined. CT scan was used to assess
SAT, so we were unable to fully assess peripheral (limb)
lipoatrophy. Finally, this analysis may have been too small
and/or of insufficient duration of follow-up to detect mean-
ingful changes in eicosanoids. Additional studies and longer-
term follow-up inHIV-infected persons are needed to further
elucidate the role of eicosanoids inmetabolic and other aging-
related comorbidities and determine their role as useful
clinical biomarkers.
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